Ariad Pharmaceuticals Inc fka ARIA

[BTH]

I think this trial will follow the same patient accrual as '534 trial did (~50 patients).

The question I have is this: are there 50 patients out there right now that would actually be ready for the trial and truly qualified (meaning, have 50 patients already progressed on Criz due to resistance or mutation?)...I just haven't looked up numbers of patients who have been treated and resisted on Criz, which is why I ask the question.

Since Criz is going to be the standard-of-care for this population, they can't just pick ALK-positive patients without a mutation or resistance... That was the initial thinking behind the trial, correct?